NO-SPA FORTE NO-SPA NO-SPA DURDGONE DROTALITE NISPAN HI-SPA HI-SPA DRT DRT DRT FORTE DROTA DROVERINE PASPA RELISPA FORTE RELISPA DESERVE DYTRA FORTE DYTRA DYTRA BIOVERINE BIOVERINE ESPASIL DROTAGIN SPANOR DOT DOT DROSPA SPA XD SPA-XD SPA X SPA-X DROPA DROVERA

Dose: 120 to 240 mg
Single Dose: 180 (180)
Frequency: 3 hourly
Route: PO
Instructions:

belongs to Papavecine. It belongs to Cholinergic muscarinic antagonist pharmacological group on the basis of mechanism of action and also classified in Antispasmodic Agent pharmacological group.The Molecular Weight of Drotaverine is 397.50.

Drotaverine is contraindicated in conditions like Cardiac insufficiency,Av block of ii &iii degree,Renal insufficiency,Hepatic insufficiency.

The severe or irreversible adverse effects of Drotaverine, which give rise to further complications include Porphyria.The symptomatic adverse reactions produced by Drotaverine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vertigo, Headache, Nausea, Vomiting, Palpitation, Constipation, Insomnia, Dry mouth, Hypotension, Dry mouth, dizziness.

Drotaverine is primarily indicated in conditions like Biliary spasm, Cholangitis, Cholecystitis, Cholecytolithiasis, Cystitis, Nephrolithiasis, Papilitis, Smooth muscle spasm, Stone formation, Ureterolithiasis, Urinary spasm, Urolithiasis, Vesical tenesmus.

No data regarding the interactions of Drotaverine was found.

Drug should not be given to Pregnant Mothers, and patients suffering from Kidney dysfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Fusidic acid is metabilized by the liver and excreted mainly through the bile, periodic liver function test should be carried out in the patient with liver dysfunction abnormalities in the biliary pathway or when the fusidic acid is given for prolonged periods, or when it is given in combination with other antibiotics which have similar excretion pathways, e.g. lincomycin and rifampicin.